<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Terapia celular > DA - CIMA - Oncología - Terapia celular - Artículos de Revista >

Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction
Authors: Herreros, J. (Jesús)
Prosper, F. (Felipe)
Perez, A. (Ana)
Gavira, J.J. (Juan José)
Garcia-Velloso, M.J. (María José)
Barba, J. (Joaquín)
Sanchez, P.L. (Pedro L.)
Cañizo, C. (C.) del
Rabago, G. (Gregorio)
Marti-Climent, J.M. (Josep María)
Hernandez, M. (Milagros)
Lopez-Holgado, N. (Natalia)
Gonzalez-Santos, J.M. (José María)
Martin-Luengo, C. (Cándido)
Alegria, E. (Eduardo)
Keywords: Non-acute myocardial infarction
Skeletal myoblasts
Coronary artery bypass
Issue Date: 2003
Publisher: Oxford University Press
Publisher version:
ISSN: 0195-668X
Citation: Herreros, J., Prósper, F., Perez, A., Gavira, J. J., Garcia-Velloso, M. J. -Velloso, Barba, J. et al. Eur. heart j. 2003, 24: 2012–2020
AIM: Experimental animal studies suggest that the use of skeletal myoblast in patients with myocardial infarction may result in improved cardiac function. The aim of the study was to assess the feasibility and safety of this therapy in patients with myocardial infarction. METHODS AND RESULTS: Twelve patients with old myocardial infarction and ischaemic coronary artery disease underwent treatment with coronary artery bypass surgery and intramyocardial injection of autologous skeletal myoblasts obtained from a muscle biopsy of vastus lateralis and cultured with autologous serum for 3 weeks. Global and regional cardiac function was assessed by 2D and ABD echocardiogram. 18F-FDG and 13N-ammonia PET studies were used to determine perfusion and viability. Left ventricular ejection fraction (LVEF) improved from 35.5+/-2.3% before surgery to 53.5+/-4.98% at 3 months (P=0.002). Echocardiography revealed a marked improvement in regional contractility in those cardiac segments treated with skeletal myoblast (wall motion score index 2.64+/-0.13 at baseline vs 1.64+/-0.16 at 3 months P=0.0001). Quantitative 18F-FDG PET studies showed a significant (P=0.012) increased in cardiac viability in the infarct zone 3 months after surgery. No statistically significant differences were found in 13N-ammonia PET studies. Skeletal myoblast implant was not associated with an increase in adverse events. No cardiac arrhythmias were detected during early follow-up. CONCLUSIONS: In patients with old myocardial infarction, treatment with skeletal myoblast in conjunction with coronary artery bypass is safe and feasible and is associated with an increased global and regional left ventricular function,improvement in the viability of cardiac tissue in the infarct area and no induction of arrhythmias.
Permanent link:
Appears in Collections:DA - CIMA - Oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Oncología - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:
File:  2003_EHJ_Herreros_Autologous intramyocardial injection of cultured skeletal muscle SC in patients with non AMI.pdf
Size:  249,06 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.